Europace Advance Access published online on June 11, 2008
Europace, doi:10.1093/europace/eun140
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation
1 Department of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan; 2 Department of Cardiovascular Research, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan
Aims: This study investigated the potential association between homocysteine levels and cardiovascular events or atrial fibrillation (AF) recurrence following radiofrequency catheter ablation (RFCA) in patients with AF.
Methods and: results Blood samples were obtained prior to the RFCA procedure. Levels of homocysteine and carboxy-terminal telopeptide of collagen type I (CITP), a collagen type I degradation marker, were measured in 96 patients receiving RFCA; 62 paroxysmal or persistent AF patients and 34 paroxysmal supra-ventricular tachycardia patients. Patients were followed up for 2.1 ± 1.5 years. Plasma homocysteine levels were significantly higher in patients with persistent AF (P < 0.05) compared with levels in paroxysmal AF and control patients. Homocysteine levels also positively correlated with left atrial dimension (LAD) (P < 0.01) and CITP levels (P < 0.001). While no significant correlation was found between basal homocysteine levels and recurrent AF after RFCA in AF patients, patients in the high homocysteine group exhibited a significantly higher rate of cardiovascular events without AF recurrence compared with those in the low homocysteine group (P < 0.05).
Conclusion: High homocysteine levels are associated with the presence of persistent AF, which is accompanied by increased CITP levels and LAD. Also confirmed is the role of homocysteine as a risk factor for the pathogenesis of cardiovascular events after RFCA in AF patients. Measurement of homocysteine level may provide useful information for the managing cardiovascular risk in patients with AF.
Key Words: Homocysteine, Arrhythmia, Atrium, Ablation
* Corresponding author. Tel: +81 52 744 2147; fax: +81 52 744 2138. E-mail address: rshibata{at}med.nagoya-u.ac.jp (R. S.); mshimano{at}med.nagoya-u.ac.jp (M. S.)
Manuscript submitted 21 March 2008. Accepted after revision 6 May 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Ravasini, P. Mossop, and C. S. McLachlan Homocysteine and heavy metal interactions in atrial fibrillation and ablation treatments Europace, December 1, 2008; 10(12): 1458 - 1458. [Full Text] [PDF]
|
|
|
|
|
|
D. R. Van Wagoner Is homocysteine a mediator of atrial dysfunction or just another marker of endothelial dysfunction? Europace, August 1, 2008; 10(8): 899 - 900. [Full Text] [PDF]
|
|